Neurocrine Biosciences, Inc. (NBIX) has announced the U.S. commercial launch of Crenessity, a treatment for adult and pediatric patients with classic congenital adrenal hyperplasia (CAH), a rare genetic disorder. This launch comes after the U.S. Food and Drug Administration approved Crenessity as an adjunct therapy to glucocorticoid replacement, aimed at controlling androgens in CAH patients.
The biopharmaceutical firm stated that Crenessity will be exclusively distributed through PANTHERx Rare, a specialty pharmacy. As of pre-market trading, Neurocrine's shares are at $134.01, representing a 0.70 percent decrease on the Nasdaq.
